Underlying EBITDA up 4.1% to NZ$86.0m, but statutory NPAT slipped 3.4%

What changed

Revenue declined 1.8% to NZ$260.6m (FY24: NZ$265.5m) and reported NPAT fell 3.4% to NZ$30.4m (FY24: NZ$31.5m). Against that, management's preferred measure — underlying EBITDA — rose 4.1% to NZ$86.0m, up from NZ$82.6m. Premium care revenue grew 12.5% to NZ$25.4m, indicating mix improvement within care. The balance sheet moved in the right direction: debt gearing eased to 36.3% from 38.3%, total assets expanded to roughly NZ$2.9bn from NZ$2.8bn (+3.6%), and all banking covenants were met. No dividend was declared.

What matters

• Divergence between underlying EBITDA (+4.1%) and statutory NPAT (−3.4%). Underlying EBITDA is a non-GAAP measure and the extracted release does not provide a full bridge from underlying EBITDA through to statutory EBIT and tax. Investors are therefore being asked to accept a 4% earnings uplift narrative that the statutory P&L does not corroborate.
• Deleveraging while asset base grew. Gearing fell ~200bps to 36.3% at the same time as assets expanded via Elmwood, Waterford and Awatere completions plus fair value movements. That combination — asset growth funded without raising gearing — is the clearest directionally positive read in the release.
• Mix shift toward premium care. Premium care revenue up 12.5% to NZ$25.4m is still a modest slice of the NZ$260.6m top line, but it is the one segment-level data point offered to support the "sharpened strategy" framing.

Expectations

No quantitative FY25 target or FY26 guidance was disclosed in the extracted materials, so the result cannot be benchmarked against a stated number. Shape context, however, is stark: HY25 revenue of NZ$132.6m represented 50.9% of the full year, but HY25 posted an NPAT loss of NZ$17.1m against a full-year NPAT of NZ$30.4m — implying second-half NPAT of roughly NZ$47.5m. The business is therefore extremely second-half weighted on the statutory line, consistent with the lumpy timing of resales and fair-value gains typical in retirement-village operators. The HY25 revenue run-rate annualised to ~NZ$265.2m, marginally above the NZ$260.6m actually delivered, so the second half was softer on revenue even as it carried all the statutory profit.

Quality of result

Quality is mixed and hard to fully verify from the extract. Positives: the underlying EBITDA uplift coincides with gearing reduction and premium-care growth, and the asset base expanded via identifiable village completions rather than revaluation alone. Caveats: statutory revenue is down, statutory NPAT is down, and the NZ$3.4m uplift in underlying EBITDA is not reconciled in the release text to statutory EBIT or PBT. The release does not disclose operating cash flow, capex, free cash flow, net debt, PBT or tax expense for FY25 in the extracted material, so cash conversion cannot be tested and the durability of the earnings improvement cannot be independently confirmed. The extreme 2H skew (−56.1% of FY25 NPAT in 1H) is structurally normal for the model but means a single half's timing drives the full-year headline.

Unresolved

• What is the bridge from underlying EBITDA NZ$86.0m to statutory EBIT, PBT and the NZ$30.4m NPAT, and which adjustments account for the 4.1% uplift?
• What were operating cash flow, capex and net debt in absolute NZ$ terms, and did cash conversion keep pace with the underlying EBITDA improvement?
• What drove the 1.8% revenue decline given sales momentum and premium care growth were both flagged positively — was it lower new-sale volumes, resale mix, or care-fee pricing?
• Why was no dividend declared, and what is the capital-allocation framework now that gearing is inside 37%?

This briefing cannot assess cash generation, capex intensity, free cash flow, or the detailed reconciliation between underlying EBITDA and statutory earnings, because those figures were not provided in the supplied extract.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.